An observational study in Crohn's Disease and Fistula, sponsored by Anterogen Co., Ltd.. Completed at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-23.
Sponsored by Anterogen Co., Ltd. · Observational
This is an open follow-up clinical trials to evaluate a sustained efficacy and safety of Adipoplus inj. for 10 months (12 months after final dose injection)after Phase II clinical trial.
1,880 studies on the registry are indexed under Crohn Disease; 462 are open to participants now.
This study's enrollment of 37 is below the median of 162 across 608 observational studies indexed under Crohn Disease.
Browse Crohn Disease studies →Anterogen Co., Ltd. is the lead sponsor of 30 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The patients who have participated in phase II clinical trial (ANTG-ASC-202) and injected with Adipoplus at least once.
Exclusion Criteria:
Number of patients with Sustained efficacy of complete closure of fistula
Proportion of patients whose fistula has been completely closed.
Time frame: Month 4, 10
Number of patients with sustained efficacy of closure of fistula
Proportion of patients with more than 50% closed of fistula (Month 2, 4, 10)
Time frame: Month 2, 4, 10
Number of patients with any adverse event
number of patients with any adverse event (Month 2, 4, 10)
Time frame: Month 2, 4, 10
Grade of Investigator's satisfaction
Grade of Investigator's satisfaction (Month 2, 4, 10) 1. very satisfaction 2. satisfacttion 3. somewhat satisfaction 4. unsatisfaction 5. very unsatisfaction
Time frame: Month 2, 4, 10
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Anterogen Co., Ltd.